Abpro Holdings (ABP) Q4 2025 earnings summary

Executive summary

• Completed a reverse recapitalization merger with Atlantic Coastal Acquisition Corp. II in November 2024, resulting in public listing and subsequent delisting from Nasdaq in February 2026; now trading on OTC Pink.

• Lead product candidates ABP-102 (immuno-oncology) and ABP-201 (ophthalmology) are in preclinical/early clinical stages, with ABP-102 IND cleared by FDA in January 2026 and Phase 1 trial planned for 2026.

• Company operates at a significant net loss, with accumulated deficit of $119.0 million as of December 31, 2025, and substantial doubt about ability to continue as a going concern.

• Ongoing legal proceedings, including settlements and unresolved claims, and material weaknesses in internal controls over financial reporting.

Financial highlights

• Net loss for 2025 was $2.9 million, improved from $7.2 million in 2024, primarily due to derecognition of liabilities and reduced R&D expenses.

• Revenue for 2025 was negligible, with no product sales and only minor R&D services revenue.

• Cash balance at year-end 2025 was $67,000, with negative cash flows from operations of $6.0 million.

• Other income in 2025 included $4.4 million derecognition of excise tax liability and $3.3 million derecognition of a Mabwell liability.

Outlook and guidance

• Management expects continued operating losses and negative cash flows; future viability depends on raising additional capital.

• Plans to initiate Phase 1/2 clinical trial for ABP-102 in 2026 and Phase 1 for ABP-201 in 2027, contingent on funding.

• No near-term product revenue expected; focus remains on milestone payments from collaborations.